AA
APGE

ALPS Advisors’s Apogee Therapeutics APGE Stock Holding History

ALPS Advisors’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.3M Buy
62,523
+16,937
+37% +$1.53M 0.04% 205
2026
Q1 		$3.84M Buy
45,586
+664
+1% +$48.2K 0.02% 296
2025
Q4 		$3.39M Buy
44,922
+22,416
+100% +$1.41M 0.02% 307
2025
Q3 		$894K Sell
22,506
-2,344
-9% -$89.5K 0.01% 552
2025
Q2 		$1.08M Sell
24,850
-8,246
-25% -$314K 0.01% 485
2025
Q1 		$1.24M Sell
33,096
-3,314
-9% -$128K 0.01% 426
2024
Q4 		$1.65M Buy
36,410
+925
+3% +$47.2K 0.01% 372
2024
Q3 		$2.08M Buy
35,485
+418
+1% +$20K 0.01% 351
2024
Q2 		$1.38M Buy
+35,067
New +$1.7M 0.01% 396

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

ALPS Advisors's APGE Position: Q2 2026 in Review

ALPS Advisors increased its Apogee Therapeutics (APGE) stake by 37% in Q2 2026, buying an estimated $1.53M and bringing the position to 62,523 shares worth $8.3M. The position accounts for 0.04% of the portfolio, ranked #205.

ALPS Advisors first reported a position in APGE in Q2 2024 and has held it in 9 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • ALPS Advisors held 62,523 shares of Apogee Therapeutics worth $8.3M as of Q2 2026.
  • ALPS Advisors bought 16,937 Apogee Therapeutics shares in Q2 2026, an estimated $1.53M.
  • Apogee Therapeutics made up 0.04% of ALPS Advisors's portfolio in Q2 2026, its #205 holding.
  • ALPS Advisors first reported a position in Apogee Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.